top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 1 day ago
  • 2 min read

Updated: 4 hours ago


01/09/2026








Novartis’s remibrutinib significantly reduced relapse rates and demonstrated a favourable safety profile in Ph3 RMS trials. (Ref)


Novartis announced positive topline results from its Ph3, REMODEL-1 and REMODEL-2 trials evaluating remibrutinib (an oral BTK inhibitor) in patients with relapsing multiple sclerosis (RMS).  


  • Both the trials met the primary endpoint, with remibrutinib significantly reducing the annualized relapse rate (ARR) vs teriflunomide.


  •  Remibrutinib demonstrated superiority vs teriflunomide on all key secondary endpoints within each trial, including reduction of MRI lesions.


  • IN a preplanned combined analysis of REMODEL-1 and REMODEL-2, remibrutinib showed a positive trend in 3mCDP and nominally significant 6mCDP.


  • Remibrutinib demonstrated a favorable safety profile with no liver safety signal, consistent with remibrutinib in chronic spontaneous urticaria (CSU).
















Adicet Bio announced completion of the last patient visit for the planned analysis of prula-cel study in patients with SLE with or without LN. (Ref)


Adicet Bio announced completion of the last patient visit for the planned Ph1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN).


  • The planned analysis includes data from 22 SLE patients with or without LN with a minimum of 6 months of follow-up, including 13 patients with at least 12 months of follow-up.


  • The Company expected to report topline data from planned analysis in September 2026.
















Alumis announced topline results from the Ph2b trail of envudeucitinib in SLE. (Ref)


Alumis Inc. announced topline results from its Ph 2b, LUMUS/ NCT05966480 trial evaluating envudeucitinib (TYK2 inhibitor) for the treatment of moderate-to-severe systemic lupus erythematosus (SLE).


  • The trial did not meet its primary and secondary endpoints in the overall trial population.


  • The responses were observed in the prespecified subgroup of patients with a high interferon gene signature (IFNGS-high), based on these findings the company planned to engage regulators on Ph3 development in SLE.


  • Envudeucitinib was generally well tolerated with no new safety signals observed.


  • Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026.


bottom of page